District of Columbia § 48-803.01 Generically equivalent drug formulary; therapeutic interchange list.

District of Columbia Statutes

§ 48-803.01 — Generically equivalent drug formulary; therapeutic interchange list.

District of Columbia § 48-803.01

Title 48Foods and Drugs.

Ch. 8Prescription Drug Price Information.

Subch. IIISubstitution of Therapeutically Equivalent Drugs.

This text of District of Columbia § 48-803.01 (Generically equivalent drug formulary; therapeutic interchange list.) is published on Counsel Stack Legal Research, covering District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

D.C. Code § 48-803.01 (2026).

Text

(a)The formulary of generically equivalent drug products for the District of Columbia shall be the chemical and generic drugs contained in the Food and Drug Administration publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” including all updates issued by the Food and Drug Administration (“Orange Book”).

(b)The Boards of Pharmacy and Medicine may jointly establish a therapeutic interchange list.

(c)If a therapeutic interchange list is established pursuant to subsection (b) of this section:

(1)The Boards of Pharmacy and Medicine shall:

(A)Revise or supplement the therapeutic interchange list as necessary;

(B)Establish procedures to allow a prescriber to consent to the substitution of therapeutically equivalent drug products without prior appr

Free access — add to your briefcase to read the full text and ask questions with AI

(a) The formulary of generically equivalent drug products for the District of Columbia shall be the chemical and generic drugs contained in the Food and Drug Administration publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” including all updates issued by the Food and Drug Administration (“Orange Book”).

(b) The Boards of Pharmacy and Medicine may jointly establish a therapeutic interchange list.

(c) If a therapeutic interchange list is established pursuant to subsection (b) of this section:

(1) The Boards of Pharmacy and Medicine shall:

(A) Revise or supplement the therapeutic interchange list as necessary;

(B) Establish procedures to allow a prescriber to consent to the substitution of therapeutically equivalent drug products without prior approval based on the therapeutic interchange list; provided, that a prescriber be allowed to limit authorization to specific conditions or patients and that no prescriber be required for any reason to consent to participation in the therapeutic interchange list; and

(C) Establish and maintain a database, searchable in real time, of those prescribers who have consented to use of the therapeutic interchange list, including any restrictions based on specific conditions or patients; and

(2) The Department of Health shall distribute the therapeutic interchange list to all pharmacies licensed in the District and shall publish it regularly in the District of Columbia Register.

(d) The Board of Pharmacy and the Board of Medicine shall maintain a link on their websites to the current list of biological products determined by the FDA to be interchangeable with a specific biological product.

Legislative History

Sept. 10, 1976, D.C. Law 1-81, title III, § 301, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 4(a), 23 DCR 8743; Mar. 11, 2010, D.C. Law 18-118, § 2(a), 57 DCR 901